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Radiotherapy has had important role in the palliation of NSCLC. Randomized trials tend to
suggest that, in general, short regimens give similar palliation and toxicity compared to
longer regimens. The benefit of combining chemotherapy to radiosensitize the palliative
radiation treatment is an open question, but so far it has not been proved to be very useful
in NSCLC. The addition of molecular targeted drugs to radiotherapy outside of approved
regimens or clinical trials warrants careful consideration for every single case and prob-
ably should not be used as a routine management. Stereotactic radiosurgery (SRS) and
stereotactic body radiation therapy (SBRT) are modern techniques being used each time
more frequently in the treatment of single or oligometastases. In general, they offer good
tumor control with little toxicity (with a more expensive cost) compared to the traditionally
fractionated radiotherapy regimens.
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INTRODUCTION
Good palliative local treatment should be simple, fast, generally
efficient, and not very expensive. Radiotherapy has largely been
used to palliate NSCLC for all these reasons (1). A good example
is the fact that one simple treatment of external beam radiation
treatment (EBRT) may stop a hemoptysis. Multiple prospective
randomized trials using different dose/fractionation schedules
have shown that palliative radiotherapy can often alleviate thoracic
and extra-thoracic symptoms in patients with locally advanced or
metastatic NSCLC (1–3).
Indications for thoracic EBRT include, but are not limited to:
hemoptysis, cough, chest pain, dyspnea, obstructive pneumonia,
dysphagia related to esophageal compression, superior vena cava
syndrome, hoarseness, or stridor. Symptoms caused by malig-
nant pleural effusion, lymphangitic carcinomatosis, and multi-
ple parenchymal diseases typically are not suitable for palliative
thoracic EBRT.
Indications for extra-thoracic EBRT include, but are not limited
to: brain, adrenal, bone, and liver metastases.
REVIEWS
In 2009, a comprehensive review involving 14 randomized clinical
trials, all related to different dose schedules to palliate the symp-
tomatic primary lung cancer, was performed by the Cochrane
Collaboration (4). In general, the results of those trials suggest
that there are not significant differences among short compared
to long radiotherapy regimens in terms of palliation, but higher-
dose regimens were associated with mild increased acute toxicity,
particularly esophagitis (Table 1). However, the studies are not
homogeneous, the end points and assessments were different, and
the reviewers did not make a clear conclusion on the ideal regi-
men of palliative radiation treatment. In fact, in clinical practice,
depending on the institution, we have seen different doses and
fractionations regimens being used for similar clinical situations. It
is very well possible that, at least in part, remuneration directs prac-
tical management. The case for bone metastases is a good example.
Despite a considerable body of evidence from randomized trials
supporting the use of a single fraction of 8 Gy for radiation ther-
apy, there is still considerable use of longer regimens such as 30 Gy
in 10 fractions (5).
TYPICAL PALLIATIVE RADIOTHERAPY DOSE AND
FRACTIONATION IN NSCLC
At the McGill University Health Centre (MUHC), we practice
evidence-based medicine preferring short and simple treatments.
Our typical palliative dose is 17 Gy in two fractions (1 week apart)
after randomized trials concluded that this regimen is simple, well
tolerated, and efficient compared to other regimens (6, 7).
SVC SYNDROME
In the past, SVC syndrome was considered a potentially life-
threatening medical emergency requiring immediate radiotherapy
as the quickest way to relieve the obstruction. Emergency radio-
therapy is no longer considered necessary for most patients (8).
Patients who present with stridor due to central airway obstruc-
tion or severe laryngeal edema represent a true medical emergency,
and these patients require immediate treatment (stent placement
and/or radiotherapy) to decrease the risk of sudden respiratory
failure and death. Evidence-based guidelines for management of
SVC syndrome are not available. Most of the malignancies caus-
ing SVC syndrome, including NSCLC, are radiation-sensitive, and
symptomatic improvement is usually apparent within 72 h, associ-
ated with complete relief of symptoms of SVC obstruction in 63%
of patients with NSCLC (9). Radiotherapy treatments are typically
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Table 1 | Randomized controlled trials assessing palliative lung radiotherapy fractionation [from Ref. (3)].
Study Year Radiotherapy schedules compared Evaluable
patients (n)
Survivala by regimen
(P =NS unless specified)
Symptom control by regimen
(P =NS unless specified)
Simpson 1985 40 Gy/20 F daily continuous/4 weeks vs.
30 Gy/10 F/2 weeks vs. 40 Gy/10 F/4 weeks,
split course
316 6.2 vs. 6.9 vs. 6.4 months No difference
Teo 1988 45 Gy/18F/3.5 weeks vs. 31.2 Gy/4 F/4 weeks 273 20 vs. 20 weeks Better with 45 Gy, P =0.012
MRC 1991 30 Gy/10 F/2 weeks or 27 Gy/6 F/2 weeks or
17 Gy/2 F/8 days
369 177 vs. 179 days No difference
MRC 1992 17 Gy/2 F/8 days vs. 10 Gy/1 fraction 235 100 vs. 122 days No difference
Abratt 1995 35 Gy/10 F/2.5 weeks vs.
45 Gy/15F/3.75 weeks
84 8.5 vs. 8.5 months No difference
MRC 1996 36 or 39 Gy/12 or 13 F/2.5 weeks vs. 17 Gy/2
F/8 days
509 1. 9 vs. 2.7 months ,
P =0.03
No difference
Rees 1997 17 Gy/2 F/8 days vs. 22.5 Gy/5 F/5 days 216 23 vs. 18% (1 year) No difference
Reinfuss 1999 50 Gy/25 F/5 weeks (conventional) vs.
40 Gy/10 F daily (split course with 4 weeks
gap) vs. delayed radiotherapy (20 25 Gy/4 or
5 F when symptomatic).
240 18 vs. 6 vs. 0%, P <0.05
(2 years)
No assessment of symptoms
Nestle 2000 32 Gy/16 F twice daily/10 days vs. 60 Gy/30
F/6 weeks
152 36 vs. 38% (1 year) No difference
Bezjak 2002 20 Gy/5 F/1 weeks vs. 10 Gy/1 F 230 6 vs. 4.2 months, P =0.03 Better for 20 Gy on Lung Cancer
Symptom Scale, P =0.009
Sundstrom 2004 17 Gy/2 F/8 days vs. 42 Gy/15 F/3 weeks vs.
50 Gy/25 F/5 weeks
407 6.8 vs. 7.0 vs. 8.2 months No difference
Erridge 2005 30 Gy/10 F/2 weeks vs. 10 Gy/1 F 148 23 vs. 28 weeks Better for 30-Gy arm, P =0.05





2005 20 Gy/5 F/l weeks vs. 16 Gy/2 F/8 days 100 5.3 vs. 8.0 months,
P =0.016
No difference
F, fraction; Gy, gray; NS, non-significant.
aSurvival given as median value or percentage at specific timepoint.
administered over a course of 1–2 weeks with larger fraction sizes
of 3–8 Gy (e.g., 17 Gy in 2 fractions, 20 Gy in 5 fractions, and 30 Gy
in 10 fractions), with the goal of achieving a more rapid response
by using larger daily doses (10).
BRACHYTHERAPY
In our Department at MUHC, we have the facilities to use
high dose rate (HDR) endobronchial brachytherapy for palli-
ation of hemoptysis or obstruction (we use doses between 6
and 10 Gy at 1 cm). Brachytherapy has been used sporadically.
Comparing brachytherapy to EBRT is difficult. There is cur-
rently no randomized or meta-analysis based evidence to recom-
mend endobronchial brachytherapy as the routine initial palliative
management of endobronchial obstruction resulting from lung
cancer (11).
The use of concurrent chemotherapy with palliative irradiation
in lung cancer.
The question if some systemic treatment should be used as a
radiosensitizer of palliative radiotherapy in NSCLC is open for
discussion. The question is pertinent because several random-
ized studies have demonstrated that, when compared with best
supportive care, chemotherapy not only significantly improves
survival but also reduces symptoms and enhances quality of life
in stage IV NSCLC. However, in palliative radiotherapy the total
dose is usually not very high (to avoid risk of radiation induced
toxicity). In general, in the group of metastatic NSCLC patients
that need local radiotherapy palliation, the addition of chemother-
apy may increase toxicity, cost, and may complicate the delivery
of the whole treatment without significant improved palliation.
At this time, it seems that there is no added benefit for the use
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of chemotherapy concurrently with radiation therapy in the pal-
liation of thoracic symptoms in lung cancer patients (3, 4), but
this is of course an open topic and indications may be discussed
in a case by case basis. There is only one randomized clinical
trial addressing this issue showing that the use of continuous-
infusion fluorouracil showed only a discrete better response but
with increased toxicity in palliation of NSCLC (12). However,
fluorouracil is not an agent currently used in NSCLC, and the avail-
able data of palliative radiotherapy with the use of other agents
commonly used today as systemic treatment in NSCLC such as
platinum based chemotherapy, vinorelbine, or gemcitabine, are
not very persuasive (13, 14).
THE USE OF TARGET AGENTS WITH PALLIATIVE
RADIOTHERAPY
When used in combination with radiotherapy, molecularly tar-
geted agents aim to increase the effect of the radiation on the
tumor. Substantial preclinical data have accumulated to show that
these agents can potentially enhance the tumor response to radio-
therapy through a variety of mechanisms (15). They offer new but
challenging possibilities for clinical practice. There is a growing
number of publications and reviews on the topic of combination
of radiotherapy and targeted therapies in many cancers, including
NSCLC (16, 17). The addition of targeted agents to thoracic radi-
ation so far has not improved outcomes in patients with locally
advanced NSCLC (18, 19).
The combination of radiotherapy and molecular agents target-
ing vascular endothelial growth factor (VEGF) mediated angio-
genesis may evolve synergistic effects leading to enhanced tumor
cell killing on the one hand, but to enhanced normal tissue dam-
age on the other hand (20). To date, there are only limited data
on the efficacy and toxicity of anti-angiogenic agents given in
combination with radiotherapy in lung cancer.
Given the strong preclinical rationale for combining EGFR
inhibitors (Cetuximab, Panitumumab, Erlotinib, Gefitinib, Lapa-
tinib, and Trastuzumab) with radiation, additional studies are cru-
cial. Phase I/II data and lack of long-term experience suggest that
physicians should consider combined modality approaches with
caution, considering the possibility of uncommon but potentially
severe toxicity (21).
With high-precision irradiation techniques (such as “stereotac-
tic body radiation therapy”), the combination with targeted agents
is feasible with apparent no increase in severe adverse events. Nev-
ertheless, the addition of molecular targeted drugs to radiotherapy
outside of approved regimens or clinical trials warrants careful
consideration for every single case.
The problem of timing is particular to radiotherapy and molec-
ularly targeted agent combination research. It cannot be assumed
that giving the drug concurrently with radiation (as it happens
with chemotherapy) is always the optimal treatment strategy.
Indeed, drugs that cause cell cycle arrest or prolong cells in the
radio-resistant phase of the cell cycle may jeopardize the radiation
effect (17).
BRAIN METASTASES
When brain metastases occur in patients with NSCLC, there
is often also active disease at the primary site or elsewhere in
the body. In few cases, the brain is the only site with active
disease (22).
There are many guidelines on the treatment of brain metastases
showing that therapeutic intervention (radiotherapy or surgery)
is associated with improved brain control (23).
Stereotactic radiosurgery (SRS) to the brain involves a single
shot of high dose radiotherapy and can control very efficiently one
to few metastases either close to the surface or deep in the brain
(24). No randomized trials compared SRS with traditional surgi-
cal resection. The traditional whole brain radiotherapy (WBRT)
(that covers the whole brain) treats the metastases and may also
prevent the growth of new metastases, but may cause side effects
such as memory loss. Recent Cochrane review shows that there is
low quality evidence that adding upfront WBRT to surgery or to
SRS decreases any intracranial disease progression at 1 year. There
is also no clear evidence of an effect on overall and progression
free survival (25).
Stereotactic radiosurgery has become increasingly important
treatment technique in the management of brain metastases, but
it is not available everywhere and it is more expensive than WBRT.
An approach of SRS alone as initial treatment of brain metastases
has allowed patients to delay or avoid WBRT and its associated
side effects. “One of the most critical questions on this topic is
how “benefit” is defined and from who’s perspective – patient,
provider, payer, or society” (26). Whether the cost of SRS in mul-
tiple brain metastases versus just WBRT approach is justified has
yet to be defined.
STEREOTACTIC BODY RADIATION THERAPY
Stereotactic body radiation therapy or “stereotactic ablative radio-
therapy” (SART) is a technique similar to SRS, but used in tumors
outside the brain. It utilizes precisely targeted high dose radiation
to the tumor while minimizing radiation to adjacent normal tissue.
It has the luxury of using 4D CT scans to manage the pulmonary
motion during treatments. This technique allows treatment of
small to moderate sized tumors, in either a single or limited num-
ber of high daily dose fractions, with high chances of local control
and little toxicity. SBRT has a role in treating selected patients with
painful bone metastases or with oligometastases in lungs, liver, or
other sites. In spine metastases, for example, non-randomized data
show good results with this technique (27). Radiation Therapy
Oncology Group (RTOG) study number 0631 is an open Phase
II/III Study of Image-Guided SBRT for localized spine metastasis
comparing one treatment of 16 Gy delivered with SBRT versus a
single fraction of 8 Gy (28).
In patients with NSCLC and with oligometastases, there is a
trend to treat them with SBRT, although there is no evidence-
based data to show that SBRT is better than traditional palliative
radiotherapy. Recently, a proposal submitted to RTOG was not
approved because many participants would consider abusive not
to offer SBRT in those cases. There is no prospective randomized
trial to answer this question. The COMET study (stereotactic abla-
tive radiotherapy for comprehensive treatment of oligometastatic
tumors (SABR-COMET) is a randomized Phase II Trial (PIs: David
Palma, and Suresh Senan) open in Europe and Canada, comparing
patients with up to five metastatic lesions from any primary tumor
site who can receive SABR. Eligible patients are randomized to
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either standard palliative radiotherapy versus SABR (with further
chemotherapy at discretion of medical oncologist).
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